Targeting Metabolic Reprogramming to Improve Breast Cancer Treatment: An In Vitro Evaluation of Selected Metabolic Inhibitors Using a Metabolomic Approach
Draguet, Anaïs; Tagliatti, Vanessa; Colet, Jean-Marie
Draguet, Anaïs ; Université de Mons > Faculté de Médecine et de Pharmacie > Service de Biologie humaine et Toxicologie
Tagliatti, Vanessa ; Université de Mons > Faculté de Médecine et de Pharmacie > Service de Biologie humaine et Toxicologie
Colet, Jean-Marie ; Université de Mons > Faculté de Médecine et de Pharmacie > Service de Biologie humaine et Toxicologie
Language :
English
Title :
Targeting Metabolic Reprogramming to Improve Breast Cancer Treatment: An In Vitro Evaluation of Selected Metabolic Inhibitors Using a Metabolomic Approach
Publication date :
22 August 2021
Journal title :
Metabolites
ISSN :
2218-1989
Publisher :
MDPI AG
Peer reviewed :
Peer Reviewed verified by ORBi
Research unit :
M125 - Biologie humaine et Toxicologie
Research institute :
R550 - Institut des Sciences et Technologies de la Santé
Fondation Contre le Cancer le Cancer en Chiffres. Available online: https://www.cancer.be/le-cancer/le-cancer-en-chiffres%0D (accessed on 20 June 2020).
Hanahan, D.; Weinberg, R.A. The Hallmarks of Cancer. Cell 2000, 100, 57–70. [CrossRef]
Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674. [CrossRef]
Azevedo-Silva, J.Ã.; Queirós, O.; Ribeiro, A.; Baltazar, F.; Young, K.H.; Pedersen, P.L.; Pretoand, A.; Casal, M. The cytotoxicity of 3-bromopyruvate in breast cancer cells depends on extracellular pH. Biochem. J. 2015, 467, 247–258. [CrossRef]
Pavlova, N.N.; Thompson, C.B. The Emerging Hallmarks of Cancer Metabolism. Cell Metab. 2016, 23, 27–47. [CrossRef]
Reid, M.; Sanderson, S.; Locasale, J. Cancer Metabolism, 6th ed.; Elsevier Inc.: Amsterdam, The Netherlands, 2017; ISBN 9783319614014.
Polanski, R.; Hodgkinson, C.L.; Fusi, A.; Nonaka, D.; Priest, L.; Kelly, P.; Trapani, F.; Bishop, P.W.; White, A.; Critchlow, S.E.; et al. Activity of the monocarboxylate transporter 1 inhibitor azd3965 in small cell lung cancer. Clin. Cancer Res. 2014, 20, 926–937. [CrossRef] [PubMed]
Beloueche-Babari, M.; Wantuch, S.; Galobart, T.C.; Koniordou, M.; Parkes, H.G.; Arunan, V.; Chung, Y.L.; Eykyn, T.R.; Smith, P.D.; Leach, M.O. MCT1 inhibitor AZD3965 increases mitochondrial metabolism, facilitating combination therapy and noninvasive magnetic resonance spectroscopy. Cancer Res. 2017, 77, 5913–5924. [CrossRef] [PubMed]
Yang, L.; Venneti, S.; Nagrath, D. Glutaminolysis: A Hallmark of Cancer Metabolism. Annu. Rev. Biomed. Eng. 2017, 19, 163–194. [CrossRef] [PubMed]
Ackerstaff, E.; Glunde, K.; Bhujwalla, Z.M. Choline phospholipid metabolism: A target in cancer cells? J. Cell. Biochem. 2003, 90, 525–533. [CrossRef] [PubMed]
Jia, M.; Andreasssen, T.; Jensen, L. Estrogen receptor a promotes breast cancer by reprogramming choline metabolism. Jpn. Cult. Stud. 2014, 167–181. [CrossRef]
Glunde, K.; Bhujwalla, Z.M.; Ronen, S.M. Choline metabolism in malignant transformation. Nat. Rev. Cancer 2011, 11, 835–848. [CrossRef] [PubMed]
Courtnay, R.; Ngo, D.C.; Malik, N.; Ververis, K.; Tortorella, S.M.; Karagiannis, T.C. Cancer metabolism and the Warburg effect: The role of HIF-1 and PI3K. Mol. Biol. Rep. 2015, 42, 841–851. [CrossRef] [PubMed]
Semenza, G.L. HIF-1: Upstream and downstream of cancer metabolism. Curr. Opin. Genet. Dev. 2010, 20, 51–56. [CrossRef]
Quintero, M.; Mackenzie, N.; Brennan, P.A. Hypoxia-inducible factor 1 (HIF-1) in cancer. Eur. J. Surg. Oncol. 2004, 30, 465–468. [CrossRef] [PubMed]
Semenza, G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 2003, 3, 721–732. [CrossRef] [PubMed]
Fu, B.; Xue, J.; Li, Z.; Shi, X.; Jiang, B.H.; Fang, J. Chrysin inhibits expression of hypoxia-inducible factor 1-α through reducing hypoxia-inducible factor-1α stability and inhibiting its protein synthesis. Mol. Cancer Ther. 2007, 6, 220–226. [CrossRef]
OMS Cancer du Sein: Prévention et Lutte Contre la Maladie Facteurs de Risque du Cancer du Sein. Available online: https://www.who.int/topics/cancer/breastcancer/fr/index2.html (accessed on 28 January 2020).
Key, T.; Verkasalo, P.; Banks, E. Epidemiology of breast cancer. Lancet Oncol. 2001, 2, 133–140. [CrossRef]
Malhotra, G.K.; Zhao, X.; Band, H.; Band, V. Histological, molecular and functional subtypes of breast cancers. Cancer Biol. Ther. 2010, 10, 955–960. [CrossRef]
Johnson-Arbor, K.; Dubey, R. Doxorubicin. In StatPearls; StatPearls Publishing: Treasure Island, FL, USA, 2020.
Dallons, M.; Schepkens, C.; Dupuis, A.; Tagliatti, V.; Colet, J.M. New Insights About Doxorubicin-Induced Toxicity to Cardiomyoblast-Derived H9C2 Cells and Dexrazoxane Cytoprotective Effect: Contribution of In Vitro 1H-NMR Metabonomics. Front. Pharmacol. 2020, 11, 1–14. [CrossRef]
Curtis, N.J.; Mooney, L.; Hopcroft, L.; Michopoulos, F.; Whalley, N.; Zhong, H.; Murray, C.; Logie, A.; Revill, M.; Byth, K.F.; et al. Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt’s lymphoma anti-tumor activity. Oncotarget 2017, 8, 69219–69236. [CrossRef] [PubMed]
Bean, J.F.; Qiu, Y.Y.; Yu, S.; Clark, S.; Chu, F.; Madonna, M.B. Glycolysis inhibition and its effect in doxorubicin resistance in neuroblastoma. J. Pediatr. Surg. 2014, 49, 981–984. [CrossRef] [PubMed]
García-Castillo, V.; López-Urrutia, E.; Villanueva-Sánchez, O.; Ávila-Rodríguez, M.A.; Zentella-Dehesa, A.; Cortés-González, C.; López-Camarillo, C.; Jacobo-Herrera, N.J.; Pérez-Plasencia, C. Targeting metabolic remodeling in triple negative breast cancer in a murine model. J. Cancer 2017, 8, 178–189. [CrossRef] [PubMed]
Schepkens, C.; Dallons, M.; Dehairs, J.; Talebi, A.; Jeandriens, J.; Drossart, L.M.; Auquier, G.; Tagliatti, V.; Swinnen, J.V.; Colet, J.M. A new classification method of metastatic cancers using a1H-NMR-based approach: A study case of melanoma, breast, and prostate cancer cell lines. Metabolites 2019, 9, 281. [CrossRef]
Martinez-Outschoorn, U.E.; Peiris-Pagés, M.; Pestell, R.G.; Sotgia, F.; Lisanti, M.P. Cancer metabolism: A therapeutic perspective. Nat. Rev. Clin. Oncol. 2017, 14, 11–31. [CrossRef]
Hirschhaeuser, F.; Sattler, U.G.A.; Mueller-Klieser, W. Lactate: A metabolic key player in cancer. Cancer Res. 2011, 71, 6921–6925. [CrossRef]
Meric-Bernstam, F.; Tannir, N.M.; Mier, J.W.; DeMichele, A.; Telli, M.L.; Fan, A.C.; Munster, P.N.; Carvajal, R.D.; Orford, K.W.; Bennett, M.K.; et al. Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), alone and in combination with everolimus (E) in patients (pts) with renal cell cancer (RCC). J. Clin. Oncol. 2016, 34, 4568. [CrossRef]
Meric-Bernstam, F. Phase 1 study of CB-839, a first-in-class, orally administered small molecule inhibitor of glutaminase in patients with refractory solid tumors. Mol. Cancer Ther. 2015, 126, 2566. [CrossRef]
Hong, C.S.; Graham, N.A.; Gu, W.; Espindola Camacho, C.; Mah, V.; Maresh, E.L.; Alavi, M.; Bagryanova, L.; Krotee, P.A.L.; Gardner, B.K.; et al. MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4. Cell Rep. 2016, 14, 1590–1601. [CrossRef]
Kwiatkowska, E.; Wojtala, M.; Gajewska, A.; Soszyński, M.; Bartosz, G.; Sadowska-Bartosz, I. Effect of 3-bromopyruvate acid on the redox equilibrium in non-invasive MCF-7 and invasive MDA-MB-231 breast cancer cells. J. Bioenerg. Biomembr. 2016, 48, 23–32. [CrossRef]
Chong, D.; Ma, L.; Liu, F.; Zhang, Z.; Zhao, S.; Huo, Q.; Zhang, P.; Zheng, H.; Liu, H. Synergistic antitumor effect of 3-bromopyruvate and 5-fluorouracil against human colorectal cancer through cell cycle arrest and induction of apoptosis. Anticancer. Drugs 2017, 28, 831–840. [CrossRef] [PubMed]
Mag, P.; Samarghandian, S.; Azimi-nezhad, M.; Borji, A.; Hasanzadeh, M.; Jabbari, F. Inhibitory and Cytotoxic Activities of Chrysin on Human Breast Adenocarcinoma Cells by Induction of Apoptosis. Pharmacogn. Mag. 2016, 12, 436–440. [CrossRef]
Khoo, B.Y.; Chua, S.L.; Balaram, P. Apoptotic Effects of Chrysin in Human Cancer Cell Lines. Int. J. Mol. Sci. 2010, 11, 2188–2199. [CrossRef] [PubMed]
Rasouli, S.; Zarghami, N. Synergistic growth inhibitory effects of Chrysin and Metformin combination on breast cancer cells through hTERT and cyclin D1 suppression. Asian Pacific J. Cancer Prev. 2018, 19, 977–982. [CrossRef]
Paris, L.; Cecchetti, S.; Spadaro, F.; Abalsamo, L.; Lugini, L.; Pisanu, M.E.; Iorio, E.; Natali, P.G.; Ramoni, C.; Podo, F. Inhibition of phosphatidylcholine-specific phospholipase C downregulates HER2 overexpression on plasma membrane of breast cancer cells. Breast Cancer Res. 2010, 12, R27. [CrossRef]
Miskimins, W.K.; Ahn, H.J.; Kim, J.Y.; Ryu, S.; Jung, Y.S.; Choi, J.Y. Synergistic anti-cancer effect of phenformin and oxamate. PLoS ONE 2014, 9, e85576. [CrossRef] [PubMed]
Hua, G.; Liu, Y.; Li, X.; Xu, P.; Luo, Y. Targeting glucose metabolism in chondrosarcoma cells enhances the sensitivity to doxorubicin through the inhibition of lactate dehydrogenase-A. Oncol. Rep. 2014, 31, 2727–2734. [CrossRef]
Abalsamo, L.; Spadaro, F.; Bozzuto, G.; Paris, L.; Cecchetti, S.; Lugini, L.; Iorio, E.; Molinari, A.; Ramoni, C.; Podo, F. Inhibition of phosphatidylcholine-specific phospholipase C results in loss of mesenchymal traits in metastatic breast cancer cells. Breast Cancer Res. 2012, 14, R50. [CrossRef]
Takeuchi, Y.; Nakayama, Y.; Fukusaki, E.; Irino, Y. Glutamate production from ammonia via glutamate dehydrogenase 2 activity supports cancer cell proliferation under glutamine depletion. Biochem. Biophys. Res. Commun. 2018, 495, 761–767. [CrossRef]
